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Abstract
Background: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit
of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate
breast cancer specific mortality in women diagnosed under the age of 40. Another limitation is the use of discrete
categories for tumour size and node status resulting in ‘step’ changes in risk estimates on moving between categories.
We have refitted the PREDICT prognostic model using the original cohort of cases from East Anglia with updated
survival time in order to take into account age at diagnosis and to smooth out the survival function for tumour size
and node status.
Methods: Multivariable Cox regression models were used to fit separate models for ER negative and ER positive
disease. Continuous variables were fitted using fractional polynomials and a smoothed baseline hazard was obtained
by regressing the baseline cumulative hazard for each patients against time using fractional polynomials. The fit of the
prognostic models were then tested in three independent data sets that had also been used to validate the original
version of PREDICT.
Results: In the model fitting data, after adjusting for other prognostic variables, there is an increase in risk of breast
cancer specific mortality in younger and older patients with ER positive disease, with a substantial increase in risk for
women diagnosed before the age of 35. In ER negative disease the risk increases slightly with age. The association
between breast cancer specific mortality and both tumour size and number of positive nodes was non-linear with a
more marked increase in risk with increasing size and increasing number of nodes in ER positive disease.
The overall calibration and discrimination of the new version of PREDICT (v2) was good and comparable to that of the
previous version in both model development and validation data sets. However, the calibration of v2 improved over v1
in patients diagnosed under the age of 40.
Conclusions: The PREDICT v2 is an improved prognostication and treatment benefit model compared with v1. The
online version should continue to aid clinical decision making in women with early breast cancer.
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Background
The PREDICT breast cancer prognostication and treat-
ment benefit prediction model (v1) was developed in 2010
[1] using data from the East Anglia Cancer Registration
and Information Centre (ECRIC) for model fitting and
data from the West Midlands Cancer Intelligence Unit for
model validation [1]. PREDICT was implemented as a
web-based tool for clinicians in January 2011 (www.pre-
dict.nhs.uk), and since then the use of the tool has in-
creased steadily. In October 2016, the website was
accessed over 20,000 times (Fig. 1a) from locations all over
the world (Fig. 1b). The model is endorsed by the
American Joint Committee on Cancer having met its cri-
teria for inclusion of risk models for individualized prog-
nosis in the practice of precision medicine [2] and is the
only breast cancer prognostic model currently available
online that has been endorsed by the American Joint
Committee on Cancer [3].
The original model used tumour size in five categories
(1–9 mm, 10–19 mm, 20–29 mm, 30–49 mm and 50 mm
+), node status in five categories (0, 1, 2–4, 5–9 and 10+
positive nodes), tumour grade (1–3), oestrogen receptor
(ER) status and mode of detection (clinical/screening) to es-
timate breast cancer-specific mortality at 5 and 10 years, as
well as age to estimate non-breast cancer mortality at 5 and
10 years. The predicted benefit of adjuvant chemotherapy
classified as first-, second- or third-generation and adjuvant
hormone therapy was taken from the meta-analyses of the
Early Breast Cancer Trialists Collaborative Group [4]. The
model was subsequently validated in independent case
series from British Columbia [5], The Netherlands [6, 7]
and Malaysia [8], as well as two additional case series from
the United Kingdom (the Prospective study of Outcomes in
Sporadic and Hereditary breast cancer [POSH] study [9]
and the Nottingham Breast Cancer Study [10]). Human
epidermal growth factor receptor 2 (HER2) status (v1.2)
Fig. 1 Web access to the online version of PREDICT at www.predict.nhs.uk, January 2011–October 2016. a Access per month. b Access by city.
Source: Google Analytics (Mountain View, CA, USA)
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and Ki67 status (v1.3) were also incorporated into the
model, resulting in small improvements in discrimination
of the model [10, 11].
Although the overall fit of the model has been good in
multiple independent case series, PREDICT has been
shown to underestimate breast cancer-specific mortality
in women diagnosed under the age of 40 years, particu-
larly those with ER-positive disease [9]. Another limita-
tion of the model is the use of discrete categories for
tumour size and node status, which result in ‘step’
changes in risk estimates on moving from one category
to the next. For example, a woman with an 18-mm or
19-mm tumour will be predicted to have the same breast
cancer-specific mortality if all the other prognostic fac-
tors are the same, whereas breast cancer-specific mortal-
ity for a 19-mm tumour will differ from that of women
with a 20-mm tumour. We have therefore re-fitted the
PREDICT prognostic model using the original cohort of
cases from East Anglia with updated survival time to
take into account age at diagnosis and to smooth out the
survival function for tumour size and node status. The
fit of the model has been tested in three independent
data sets that have also been used to validate the original
version of PREDICT.
Methods
Patient data
Model development data
The primary analysis was based on data from patients
with invasive breast cancer diagnosed in East Anglia, UK,
between 1999 and 2003 identified by ECRIC. ECRIC cov-
ered a catchment area population of approximately 5.5
million people and registers all malignant tumours occur-
ring in people resident in East Anglia at the time of diag-
nosis. ECRIC also recorded prospectively demographic,
pathologic, staging, general treatment and outcome infor-
mation. Death certificate flagging through the Office for
National Statistics provides the registries with notification
of deaths. The lag times for this are a few weeks for cancer
deaths and 2 months to 1 year for non-cancer deaths. In
addition, ECRIC staff checked vital status by querying the
National Health Service Strategic Tracing Service. Vital
status was ascertained at the end of June 2013, and all
analyses were censored on 31 December 2012 to allow for
delay in reporting of vital status. Breast cancer-specific
mortality was defined as deaths where breast cancer was
listed as the cause of death on part 1a, 1b or 1c of the
death certificate.
Information obtained from ECRIC included age at
diagnosis, number of lymph nodes sampled and number
of lymph nodes positive, tumour size, histological grade,
ER status, mode of detection (screening vs. clinical), in-
formation on local therapy (wide local excision, mastec-
tomy, radiotherapy), and type of adjuvant systemic
therapy (chemotherapy, endocrine therapy, both). Exact
chemotherapy regimens are unknown, but the majority
of patients with breast cancer in the ECRIC population
received first- or second-generation chemotherapy dur-
ing this time period. Patients who did not undergo sur-
gery, patients with incomplete local therapy (wide local
excision without radiotherapy) and patients with fewer
than four nodes excised with a diagnosis of node-
negative disease were excluded from the analyses, leav-
ing a study population of 5738 individuals. Of these
1977 (34%) had less than 10 years of potential follow-up.
Validation samples
From the Nottingham/Tenovus Breast Cancer Study
(NTBCS), data were available for 2232 cases of inva-
sive breast cancer treated in Nottingham from 1989
to 1998. Of these, 506 node-negative cases were ex-
cluded because of inadequate axillary node staging
(fewer than four nodes sampled), leaving 1726 pa-
tients (ER-negative, n = 452; ER-positive, n = 1274) for
the validation study. Outcome data were obtained on
a prospective basis. Patients were followed at 3-
month intervals initially, then at 6-month intervals,
and then annually for a median period of 111 months
(range 4–211 months). At death, the hospital notes
are examined and deaths allocated to with/from
breast cancer or to without known breast cancer. For
those who were lost to follow-up, hospital notes were
retrieved and checked. Vital status was ascertained at
the end of October 2012. Breast cancer-specific mor-
tality was defined as deaths where breast cancer was
listed as the cause of death on part 1a, 1b or 1c of
the death certificate. Breast cancer-specific survival
was defined as the interval between the operation and
death resulting from breast cancer, death being scored
as an event, and patients who died as a result of
other causes or were still alive were censored at the
time of last follow-up.
For the Breast Cancer Outcome Study of Mutation
Carriers (BCOS), data collection has been described
previously [7]. In short, we used data from a
hospital-based cohort of consecutive females diag-
nosed at <50 years of age with invasive breast can-
cer, identified through medical registries of
participating hospitals or the Netherlands Cancer
Registry. Patients diagnosed between 1990 and 2000
with unilateral stages I–III breast cancer without a
previous cancer diagnosis (except non-melanoma
skin cancer), for whom complete data on tumour
size, nodal status, receipt of adjuvant systemic ther-
apy, and follow-up were available, were included. In-
formation about diagnosis and treatment (e.g.,
histological tumour grade, stage, adjuvant chemo-
therapy and endocrine systemic treatment; before
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about 2004 no trastuzumab was administered), ER
and progesterone receptor status, HER2 and angio-
lymphatic invasion were gathered from original path-
ology reports and/or determined using reviews of
whole slides and staining of tumours in tissue micro-
arrays. Follow-up data were obtained from the med-
ical registries from the participating hospitals and/or
linkage with the Dutch municipal registry through
the Netherlands Cancer Registry (last follow-up up-
date in 2013).
The Prospective Study of Outcomes in Sporadic and
Hereditary Breast Cancer (POSH) is a multicentre
prospective observational cohort study of 2609 young
women diagnosed with breast cancer in the United
Kingdom between 2000 and 2008 [12]. Information
obtained in the POSH cohort included age at diagno-
sis, histological grade, tumour size, number of positive
lymph nodes, ER status, adjuvant chemotherapy,
chemotherapy regimen and adjuvant hormone therapy.
Outcome data were obtained through flagging with
the Office for National Statistics. Vital status was
ascertained at the end of June 2015, and all analyses
were censored on 31 December 2014 to allow for
delay in reporting of vital status. Breast cancer-specific
mortality was defined as deaths where breast cancer
was listed as the cause of death on part 1a, 1b or 1c
of the death certificate. A total of 1374 of the partici-
pants (53%) had less than 10 years of potential follow-
up. The validation studies were approved by the rele-
vant research ethics committees, and all participants
provided written informed consent.
Statistical methods
Separate models were derived for ER-positive and
ER-negative breast cancer. The models were derived
using Cox regression to estimate the coefficients as-
sociated with each risk factor. The non-linear risk
relationships between continuous variables (age,
tumour size and number of positive nodes) and
breast cancer death were modelled using multivari-
able fractional polynomials [13]. The variables for
the final models were selected by sequential back-
ward elimination [14]. The effects of adjuvant
chemotherapy and adjuvant hormone therapy were
constrained to the effects reported for standard
anthracycline-based chemotherapy and adjuvant tam-
oxifen from an updated analysis of the Early Breast
Cancer Trialists Collaborative Group [15]. After fit-
ting of the models, smoothed functions for baseline
hazard of breast cancer-specific mortality were de-
rived as follows. First, the baseline cumulative haz-
ard was estimated for each patient. Then the
logarithmic value of the baseline hazard was
regressed against time using a univariate fractional
polynomial function. The resulting functions were
used to estimate the cumulative baseline hazard at
10 years.
A similar approach was used to model non-breast
cancer mortality using Cox regression and multivari-
able fractional polynomials to obtain a function for
other mortality with age. The smoothed baseline haz-
ard function for non-breast-specific mortality was de-
rived as described above.
Table 1 Fractional polynomial functions and associated logarithmic HRs for age at diagnosis, tumour size, number of positive nodes,
tumour grade and mode of detection by oestrogen receptor status
Prognostic factor Function Log HR P value
ER-negative breast cancer specific mortality
Age = age − 56.325 0.00894 0.025
Tumour size, mm = (size/100)1/2 − 0.5090 2.109 <0.0001
Number of positive nodes =1/[(nodes + 1)/10] 1/2 − 1.72 −0.705 <0.0001
Grade = grade 0.259 0.028
ER-positive breast cancer-specific mortality
Age 1 = (age/10)−2 − 0.0287 34.53 0.001
Age 2 = (age/10)−2 × ln(age/10) − 0.0510 −34.20 0.001
Tumour size, mm = ln(size/100) + 1.5452 0.7531 <0.0001
Number of positive nodes = ln((nodes + 1)/10) + 1.3876 0.7069 <0.0001
Grade = grade 0.7467 <0.0001
Screen-detected screen detected = 1 −0.2763 0.016
Non-breast cancer mortality
Age = (age/10)2 − 34.234 0.0698 <0.0001
ER Oestrogen receptor
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Fig. 2 Breast cancer-specific mortality HR functions for age, tumour size and number of positive nodes derived from the model development
data. ER-negative is indicated by red lines; ER-positive is indicated by blue lines. ER Oestrogen receptor
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Calculation of predicted mortality for validation sample
A prognostic index (PI) for each patient was calcu-
lated as the sum of the weighted prognostic factors
where the weights were the β-coefficients from the
Cox regression and the logarithmic HRs for the ef-
fects of adjuvant chemotherapy and hormone therapy
from clinical trials. A non-breast cancer mortality
index (MI) was calculated as the weighted prognostic
factor for non-breast cancer mortality. The absolute
risk of breast cancer death (HB) before time t, assum-
ing no competing mortality, is estimated by the fol-
lowing formula:
HB ¼ 1 ‐ exp ‐ exp PIð Þ  BSbtð Þ
and the equivalent formula for the cumulative risk of
non-breast cancer mortality (HO) is:
HO ¼ 1 ‐ exp ‐ exp MIð Þ  BSotð Þ
where BSbt is the cumulative baseline hazard for breast
cancer mortality at time t and BSot is the cumulative
baseline hazard for non-breast cancer mortality at time
t.
These are competing risks, so the cumulative risk of
breast cancer mortality at time t is
Rb ¼ HB  1 – HOð Þ
and the cumulative risk of non-breast cancer mortality is
Ro ¼ HO  1 – HBð Þ
We also estimated the 10-year predicted breast cancer-
specific mortality and other mortality using the current
online version of PREDICT (v1.3).
Model calibration was analysed as a comparison of the
predicted mortality estimates from each model with the
observed mortality. In addition to comparing calibration
in the complete data set, we evaluated calibration within
strata of other prognostic variables. We also evaluated
calibration within quintiles of predicted mortality. A
goodness-of-fit test was carried out by using a χ2 test
based on the observed and predicted number of events
within each quintile (5 df ). Model discrimination was
Fig. 3 Age-specific HR for non-breast cancer mortality derived from the model development data. ER-negative is indicated by red lines; ER-
positive is indicated by blue lines. ER Oestrogen receptor
Table 2 Observed and predicted (PREDICT v2) deaths, by cause
of death and data set
Study Number Observed Predicted Difference (%) P value
Total mortality
ECRIC 5738 1550 1600 3 0.21
BCOS 981 255 270 6 0.34
NTBCS 1944 488 468 −4 0.36
POSH 2609 544 621 12 0.00
Total 11,272 2837 2958 4 0.023
Breast cancer-specific mortality
ECRIC 5738 932 953 2 0.48
BCOS 981 227 244 7 0.25
NTBCS 1944 325 331 2 0.74
POSH 2609 527 581 9 0.018
Total 11,272 2011 2110 5 0.027
Non-breast cancer mortality
ECRIC 5738 618 646 4 0.25
BCOS 981 28 26 −9 0.66
NTBCS 1944 163 137 −19 0.039
POSH 2609 17 39 57 <0.001
Total 11,272 826 848 3 0.44
Abbreviations: BCOS Breast Cancer Outcome Study of Mutation Carriers, ECRIC
Eastern Cancer Registration and Information Centre, NTBCS Nottingham/
Tenovus Breast Cancer Study, POSH Prospective study of Outcomes in
Sporadic and Hereditary breast cancer
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Table 3 Observed and predicted breast cancer specific mortality at ten years in model fitting data set by estrogen receptor status,
age at diagnosis, tumour size, nodes positive and tumour grade
Number
cases
Number of deaths PREDICT v1 PREDICT v2
PREDICT v1 PREDICT v2 Observed Predicted − observed (%) P-value Predicted − observed (%) P-value
Age at diagnosis
ER negative
20–29 11 3.6 3.7 4 -11 0.81 -7 0.88
30–39 105 32.5 34.5 40 -19 0.19 -14 0.35
40–49 210 60.8 66.1 60 1 0.92 10 0.45
50–59 304 88.7 94.7 88 1 0.94 8 0.49
60–69 200 62.8 64.6 63 0 0.98 3 0.84
70–79 190 77.9 67.4 78 0 0.99 -14 0.20
Total 1020 326.3 331.1 333 -2 0.71 -1 0.92
ER positive
20–29 12 1.5 3.3 5 -70 0.004 -34 0.35
30–39 209 38.9 43.1 43 -10 0.51 0 0.99
40–49 765 108.9 112.3 107 2 0.86 5 0.62
50–59 1556 171.6 162.8 157 9 0.26 4 0.65
60–69 1214 157.2 142.5 139 13 0.15 3 0.77
70–79 962 198.6 162.4 148 34 0.0003 10 0.26
Total 4718 676.7 626.4 599 13 0.0028 5 0.27
Tumour size (mm)
ER negative
0–9 57 6.9 8.8 9 -23 0.43 -2 0.94
10–19 324 65.6 77.6 73 -10 0.36 6 0.60
20–29 337 102.3 105.5 108 -5 0.58 -2 0.81
30–49 218 95.3 86.6 90 6 0.58 -4 0.72
50+ 84 56.0 52.5 53 6 0.69 -1 0.94
Total 1020 326.3 331.1 333 -2 0.71 -1 0.92
ER positive
0–9 528 19.0 15.7 11 72 0.07 42 0.24
10–19 1976 145.7 149.0 129 13 0.17 15 0.10
20–29 1329 221.4 205.9 217 2 0.77 -5 0.44
30–49 665 194.8 168.1 161 21 0.015 4 0.58
50+ 220 95.8 87.8 81 18 0.13 8 0.47
Total 4718 676.7 626.4 599 13 0.0028 5 0.27
Nodes positive
ER negative
0 536 103.7 101.6 107 -3 0.75 -5 0.59
1 150 41.7 48.5 49 -15 0.26 -1 0.95
2–4 168 71.1 76.8 68 5 0.71 13 0.31
5–9 92 53.7 53.5 57 -6 0.65 -6 0.63
10+ 74 56.0 50.5 52 8 0.59 -3 0.84
Total 1020 326.3 331.1 333 -2 0.71 -1 0.92
ER positive
0 2832 182.7 188.4 180 1 0.84 5 0.54
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evaluated by calculating the AUC calculated for 10-year
mortality. This is a measure of how well each version of
the model identifies those patients with worse survival.
The AUC is the probability that the predicted mortality
of a randomly selected patient who died will be higher
than the predicted mortality of a randomly selected sur-
vivor. Comparison between the new model and v1 was
made using the method of DeLong [16]. A goodness-of-
fit test was carried out by using a χ2 test based on the
observed and predicted number of events in quintiles of
predicted risk (5 df ). All analyses were carried out using
Stata version 14 software (StataCorp, College Station,
TX, USA).
Results
The model fitting was carried out using data for 1020
women with ER-negative disease, 333 of whom had died as
a result of breast cancer and 107 of whom had died as a re-
sult of other causes within 10 years of follow-up, as well as
data for 4718 women with ER-positive breast cancer, 599 of
whom had died as a result of breast cancer and 511 of
whom had died as a result of other causes within 10 years
of follow-up. Tumour size, number of positive nodes and
tumour grade were significant prognostic factors for ER-
negative disease in the Cox regression implemented within
a multivariable fractional polynomial model. For ER-
positive disease, age at diagnosis, tumour size, number of
positive nodes, tumour grade and mode of detection were
significant. The fractional polynomial functions and associ-
ated logarithmic HRs are shown in Table 1.
The breast cancer-specific mortality HR functions
for age at diagnosis, tumour size and number of posi-
tive nodes are shown in Fig. 2. In ER-positive disease,
after adjusting for other prognostic variables, there is
an increase in risk of breast cancer-specific mortality
in younger and older patients, with a substantial in-
crease in risk for women diagnosed before the age of
35 years. The association between breast cancer-
specific mortality and both tumour size and number
of positive nodes was non-linear, with a more marked
increase in risk with increasing size and increasing
number of nodes in ER-positive disease. The corre-
sponding baseline survival functions are given by the
following equations:
BSbt ER negativeð Þ ¼ ‐1:156 þ 0:4707=t2‐ 3:514=t
BSbt ER positiveð Þ ¼ 0:7424 ‐ 7:530=t1=2‐ 1:813
 ln tð Þ=t1=2
The age-specific HRs for non-breast cancer mortality
are shown in Fig. 3. The relevant baseline survival func-
tion is:
BSot non‐breast mortalityð Þ
¼ ‐6:053 þ 1:080  ln tð Þ þ 0:3255  t1=2
Model calibration
The observed and predicted numbers of deaths from
breast cancer and deaths from other causes are shown in
Table 2. While there was no significant differences in the
Table 3 Observed and predicted breast cancer specific mortality at ten years in model fitting data set by estrogen receptor status,
age at diagnosis, tumour size, nodes positive and tumour grade (Continued)
1 703 87.1 86.7 69 26 0.05 26 0.057
2–4 713 169.3 146.9 136 25 0.01 8 0.37
5–9 304 129.8 113.9 122 6 0.49 -7 0.45
10+ 166 107.7 90.4 92 17 0.13 -2 0.87
Total 4718 676.7 626.4 599 13 0.0028 5 0.27
Grade
ER negative
1 27 4.0 4.9 2.9 38 0.58 70 0.36
2 240 62.8 69.4 75.8 -17 0.10 -8 0.44
3 753 259.5 256.7 235.8 10 0.14 9 0.19
Total 1020 326.3 331.1 314.5 4 0.51 5 0.36
ER positive
1 963 34.2 36.2 30 14 0.47 21 0.30
2 2696 319.2 305.1 296 8 0.19 3 0.60
3 1059 323.3 285.0 273 18 0.0051 4 0.48
Total 4718 676.7 626.4 599 13 0.0028 5 0.27
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Table 4 Observed and predicted breast cancer specific mortality at ten years in combined validation data sets by estrogen receptor
status, age at diagnosis, tumour size, nodes positive and tumour grade
Number
cases
Number of deaths PREDICT v1 PREDICT v2
PREDICT v1 PREDICT v2 Observed Predicted − observed (%) P-value Predicted − observed (%) P-value
Age at diagnosis
ER negative
20–29 92 27.1 25.6 24 13 0.55 6 0.76
30–39 855 246.8 246.8 226 9 0.18 9 0.18
40–49 414 130.9 124.4 122 8 0.41 2 0.83
50–59 165 48.7 46.3 45 8 0.60 3 0.85
60–69 117 35.9 33.8 28 28 0.19 21 0.32
70–79 11 3.0 2.8 1 202 0.24 180 0.28
Total 1654 492.4 479.7 446 11 0.034 8 0.12
ER positive
20–29 140 24.3 47.7 34 -28 0.050 40 0.047
30–39 1633 276.0 316.5 304 -9 0.092 4 0.48
40–49 1063 203.3 186.0 167 22 0.010 11 0.16
50–59 467 56.6 51.1 49 16 0.31 4 0.77
60–69 517 72.9 66.9 72 1 0.91 -7 0.53
70–79 55 9.9 8.8 7 41 0.36 26 0.54
Total 3875 643.0 677.1 633 2 0.67 7 0.09
Tumour size (mm)
ER negative
0–9 96 11.1 13.3 12 -7 0.79 10 0.73
10–19 559 108.9 118.9 110 -1 0.92 8 0.41
20–29 524 149.9 144.3 140 7 0.42 3 0.72
30–49 354 150.2 131.4 130 16 0.10 1 0.91
50+ 121 72.9 71.8 54 35 0.027 33 0.04
Total 1654 493.0 479.7 446 11 0.034 8 0.12
ER positive
0–9 352 20.2 17.5 27 -25 0.13 -35 0.024
10–19 1428 130.7 142.2 151 -13 0.076 -6 0.46
20–29 1111 188.6 195.5 192 -2 0.81 2 0.80
30–49 695 180.7 189.5 165 10 0.24 15 0.07
50+ 289 123.3 132.3 98 26 0.023 35 0.00
Total 3875 643.7 677.1 633 2 0.67 7 0.09
Nodes positive
ER negative
0 937 180.2 165.3 167 8 0.33 -1 0.89
1 232 64.4 70.0 60 7 0.58 17 0.23
2–4 300 127.8 132.1 117 9 0.34 13 0.19
5–9 101 58.9 57.2 55 7 0.61 4 0.77
10+ 84 61.7 55.1 47 31 0.062 17 0.28
Total 1654 493.0 479.7 446 11 0.034 8 0.12
ER positive
0 2,085 169.0 190.6 188 -10 0.14 1 0.85
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observed and predicted numbers of breast cancer deaths
for the model fitting data, NTBCS or BCOS, the
predicted number of breast cancer deaths was slightly
over-estimated for POSH (P = 0.018). The number of
predicted deaths from other causes was significantly
lower than that observed for NTBCS (P = 0.039) and sig-
nificantly higher for POSH (P < 0.001).
The observed and predicted (v1 and v2) breast cancer
deaths in the model development data set by age at diag-
nosis, tumour size, nodes positive and tumour grade are
shown in Table 3. Overall, the calibration of PREDICT v1
and v2 was good for ER-negative disease (observed breast
cancer deaths 333 compared with 326 predicted by PRE-
DICT v1 and 330 by PREDICT v2). PREDICT v1 overesti-
mated the number of breast cancer deaths in women with
ER-positive breast cancer by 13% (599 observed compared
with 677 predicted, P = 0.003). However, the number of
breast cancer deaths in younger women with ER-positive
disease was underestimated, whereas that in older women
was overestimated. In contrast, the calibration of PRE-
DICT v2 was very good for ER-positive disease (626 pre-
dicted, P = 0.27).
Table 4 shows the observed and predicted (v1 and v2)
breast cancer deaths in the combined validation data
sets by ER status, age at diagnosis, tumour size, nodes
positive and tumour grade. The results by individual
data set and ER status for age at diagnosis, tumour size,
nodes positive and tumour grade are shown in Add-
itional file 1: Tables S1–S4. PREDICT v1 over-estimated
the number of breast cancer deaths in ER-negative cases
by 11% (446 observed compared with 492 predicted, P =
0.034). This over-estimation was most notable in the lar-
ger tumours and in the high-grade tumours. In contrast,
the calibration of PREDICT v2 in ER-negative cases was
better (predicted 480, P = 0.12). The calibration of both
PREDICT v1 and PREDICT v2 was good in ER-positive
cases (observed breast cancer deaths 633 compared with
643 [P = 0.67] and 677 [P = 0.09] predicted by v1 and v2,
respectively). However, as previously described, PRE-
DICT v1 under-estimated breast cancer-specific mortal-
ity in women diagnosed with ER-positive disease
diagnosed under 50 years of age. In contrast, PREDICT
v2 slightly over-predicted the number of breast cancer
deaths in women diagnosed under the age of 30 years
(48 predicted vs. 34 observed, P = 0.047). Both PREDICT
v1 and v2 tended to under-estimate breast cancer mor-
tality in women with small ER-positive tumours and
over-estimate mortality in women with larger ER-
positive tumours.
Model discrimination
The PREDICT model discrimination by data set is
shown in Table 5. The AUC in the model-fitting data
was similar for PREDICT v1 and v2 for ER-negative dis-
ease (0.724 and 0.726, P = 0.67), whereas the AUC was
slightly smaller for v1 than v2 in ER-positive disease
(0.791 and 0.796, P = 0.028). The AUC values for PRE-
DICT v1 and v2 were similar in the individual validation
sets for both ER-negative and ER-positive disease, al-
though in the combined validation data, PREDICT v2
performed slightly better for ER-positive disease than for
ER-negative disease (AUC 0.760 vs. 0.750, P = 0.016).
Table 4 Observed and predicted breast cancer specific mortality at ten years in combined validation data sets by estrogen receptor
status, age at diagnosis, tumour size, nodes positive and tumour grade (Continued)
1 675 97.8 109.1 100 -2 0.83 9 0.39
2–4 734 187.8 187.5 181 4 0.62 4 0.63
5–9 245 109.6 109.5 94 17 0.14 17 0.14
10+ 136 79.5 80.3 70 14 0.29 15 0.25
Total 3875 643.7 677.1 633 2 0.67 7 0.09
Grade
ER negative
1 44 6.2 7.3 7 -12 0.74 4 0.91
2 183 41.7 45.6 39 7 0.68 17 0.33
3 1427 445.1 426.8 400 11 0.033 7 0.19
Total 1654 493.0 479.7 446 11 0.034 8 0.12
ER positive
1 658 29.4 31.4 27 9 0.66 16 0.43
2 1730 212.1 230.8 219 -3 0.64 5 0.44
3 1487 402.2 414.9 387 4 0.45 7 0.17
Total 3875 643.7 677.1 633 2 0.67 7 0.09
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Goodness of fit
The observed and predicted breast cancer deaths by
quintile of predicted risk for PREDICT v2 are shown in
Fig. 4a for the model development data and in Fig. 4b
for the validation data. The observed values differed sig-
nificantly from the predicted for the ER-positive cases in
the validation data (χ2 = 13.2, 5 df, P = 0.020), with a
slight over-estimation in the highest risk quintile (325
deaths predicted vs. 293 observed).
Discussion
We have refitted the prognostic model underlying the
PREDICT breast cancer prognostication and treatment
benefit tool using the original data used to develop the
model with updated survival time data and using a
sophisticated approach to modelling the data with multi-
variable fractional polynomial models in a Cox regres-
sion framework. The association between tumour size
and node status with prognosis is, of course, well-
established, but the difference in the shape of the non-
linear associations in ER-positive and ER-negative
disease has not previously been described. Similarly,
multiple studies have reported an association of young
age at diagnosis with a poor prognosis (e.g., [17–21]),
but those studies that have used multivariable models
have simply adjusted for ER status and as a result have
not reported the notable difference in the age-specific
relative hazards between ER-positive and ER-negative
disease demonstrated by our analysis.
The calibration of the new model is better than that of
the original model for breast cancer-specific mortality in
the model development data set. In three independent
validation data sets, the calibration of PREDICT v1 and
v2 is similar, with v1 being slightly better for ER-positive
disease and v2 being slightly better for ER-negative dis-
ease. There was little difference in the discrimination of
PREDCIT v2 compared with v1 for ER-negative disease,
but for ER-positive disease, v2 performed slightly better
in both model-fitting and validation data sets.
Prediction of non-breast cancer deaths was excellent in
the model development data set but not as good in the
validation data sets. The under-prediction of non-breast
Fig. 4 Observed and predicted breast cancer deaths at 10 years by
quintile of predicted risk. a Model development data. b Validation
data. ER-negative is indicated by red lines; ER-positive is indicated by
blue lines. ER Oestrogen receptor
Table 5 Comparison of discrimination (AUCs) of PREDICT v1
and PREDICT v2, by data set and oestrogen receptor status
Study ER status Predict v1 Predict v2 P value
ECRIC Negative 0.724 0.726 0.67
ECRIC Positive 0.791 0.796 0.028
ECRIC All 0.801 0.805 0.014
BCOS Negative 0.650 0.632 0.87
BCOS Positive 0.737 0.741 0.52
BCOS All 0.737 0.734 0.45
NTBCS Negative 0.671 0.680 0.32
NTBCS Positive 0.787 0.790 0.57
NTBCS All 0.770 0.772 0.63
POSH Negative 0.717 0.715 0.76
POSH Positive 0.741 0.746 0.36
POSH All 0.735 0.741 0.22
Combined validation Negative 0.698 0.696 0.70
Combined validation Positive 0.750 0.760 0.016
Combined validation All 0.747 0.752 0.058
Abbreviations: BCOS Breast Cancer Outcome Study of Mutation Carriers, ECRIC
Eastern Cancer Registration and Information Centre, NTBCS Nottingham/
Tenovus Breast Cancer Study, POSH Prospective study of Outcomes in
Sporadic and Hereditary breast cancer
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cancer deaths in the NTBCS data set is likely to be partly
due to the fact that this is a cohort diagnosed in the
1980s, when population death rates were higher than at
the time the model development cohort was ascertained.
Non-breast cancer mortality was also under-predicted in
the BCOS case series, which was ascertained in the 1990s,
although this under-prediction was not significant. Other
mortality was significantly over-predicted in the POSH
case series. Because this case series is almost contempor-
aneous with the model development cases, differences in
population mortality rates are unlikely to be the explan-
ation. However, the participation of eligible women in
POSH is liable to be subject to a healthy cohort bias, with
women with better general health being more likely to
participate than those with poorer general health.
The PREDICT model was originally developed using data
from patients treated in the United Kingdom between 1999
and 2003. Since then, there have been several advances in
breast cancer treatment, including the introduction of sen-
tinel node biopsy, intensity-modulated radiotherapy, tar-
geted therapies such as trastuzumab, and taxane-based
(third-generation) chemotherapy. As a result, the original
model has been updated to include the prognostic effect of
HER2 status and the benefit of trastuzumab. Although the
majority of the model development cohort who received
adjuvant chemotherapy were treated with second-
generation regimens, the POSH validation cohort was diag-
nosed and treated during 2000–2007, and many were
treated using taxane-based adjuvant chemotherapy.
Conclusions
In an era of precision oncology, accurate, well-validated
models that predict patient outcomes are invaluable
clinical tools. We have derived an improved version of
the PREDICT prognostication and treatment benefit
model to reduce some of the limitations of the original
model. The new model has been validated in three inde-
pendent data sets and performs well. It has been imple-
mented online and will continue to aid clinical decision
making in clinical practice.
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